Health & Veritas Kate Heilpern: Jumping into the Deep End
Howie and Harlan are joined by Kate Heilpern, president of Yale New Haven Hospital, to discuss the innovation and adaption needed to lead NewYork-Presbyterian Hospital through the worst of the COVID-19 pandemic, and how Yale New Haven Health structures itself to provide quality care across five hospitals. Harlan reflects on the many biotech startups emerging from Yale; Howie responds to the Trump administration's assertion of a link between acetaminophen and autism.
Links:
Biotech at Yale and Beyond
“Investors Flock Back to Biotech After a Long, Cold Spell
“Boom, Bust and Recover: What Happens Next as Biotech VC Cycle Resets”.
“Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion”
Health & Veritas Ep. 80: Josh Geballe: Turning Yale Innovation into Startups
Yale Ventures Annual Report 2025
“BioMarin to buy rare disease drugmaker Inozyme for $270M”
“Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018”
Kate Heilpern
“Yale New Haven Hospital announces new president”
“Heilpern sees society reflected in the busy ER”
“Meet the Heroes Fighting on the Front Lines Against Covid-19”
“’Adrenaline, Duty, and Fear’: Inside a New York Hospital Taking on the Coronavirus”
Health & Veritas Ep. 116: Christopher O’Connor: Hospital Leadership in Trying Times
“The 600 Pathways Yale New Haven Health Takes to Improved Care Delivery”
Tylenol and Autism
“Trump Issues Warning Based on Unproven Link Between Tylenol and Autism”
“Trump links autism and Tylenol: is there any truth to it?”
“The U.S. government has jumped the public health shark”
Learn more about the MBA for Executives program at Yale SOM.